Tesamorelin
Also known as: Egrifta, TH9507, GHRH(1-44) analog, growth hormone-releasing factor analogue, GHRH analogue
Growth hormone-releasing hormone (GHRH) analogue / synthetic growth hormone secretagogue
What it is
Tesamorelin is the active ingredient in Egrifta, an FDA-approved treatment for excess belly fat in people with HIV-associated lipodystrophy. It works by stimulating the pituitary to release growth hormone, which reduces visceral fat. Prescription-only for that indication; also being studied for cognitive function and fatty liver in HIV patients.
The scientific side
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates the synthesis and release of endogenous growth hormone (GH) from the pituitary gland in an episodic, pulsatile manner. By augmenting pulsatile GH secretion, tesamorelin subsequently increases insulin-like growth factor-1 (IGF-1) levels. This GH/IGF-1 axis augmentation selectively reduces visceral adipose tissue (VAT) without significantly affecting subcutaneous adipose tissue. Unlike exogenous GH administration, tesamorelin acts physiologically through the pituitary gland, restoring a more normal GH secretion profile.
Class: Growth hormone-releasing hormone (GHRH) analogue / synthetic growth hormone secretagogue
At a glance
| What it is | A synthetic analog of growth hormone-releasing hormone (GHRH): the 44 amino acids of human GHRH plus a small fatty-acid group that makes it last longer. |
|---|---|
| Approved for | Reducing excess abdominal fat in adults with HIV who have lipodystrophy. |
| Brand names | Egrifta (2010), Egrifta SV, Egrifta WR (2025). Prescription only. |
| Route | Injection under the skin of the abdomen, once a day. |
| Label dose | 1.4 mg daily (Egrifta SV) or 1.28 mg daily (Egrifta WR). The original Egrifta dose was 2 mg. |
| Main effect | About 15-18% less visceral (deep belly) fat after 26 weeks in the phase 3 trials. It is weight-neutral, not a weight-loss drug. |
| Key risks | Raised blood sugar, raised IGF-1, fluid retention and joint pain, injection-site reactions. |
What is Tesamorelin?
Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH), the signal the brain uses to tell the pituitary gland to release growth hormone. The FDA label describes it as "the 44 amino acid sequence of human GRF and a hexenoyl moiety" attached at one end, a change that makes it resist breakdown.
It is made by Theratechnologies and sold in the US as Egrifta SV and Egrifta WR. Unlike most peptides on this site it went through full phase 3 trials and FDA approval. Outside that approval it is also used off-label, and like Sermorelin and CJC-1295 it is a GHRH analog.
How does it work?
Tesamorelin binds GHRH receptors on the pituitary, which then releases the body's own growth hormone in pulses. Growth hormone raises IGF-1 and breaks down fat, with the strongest effect on visceral fat around the organs. Because it works through the pituitary, it needs a working hypothalamic-pituitary axis, which is why people with pituitary damage or removal cannot use it.
It is not growth hormone itself. In the trials, IGF-1 rose by about 105-122 ng/mL more than with placebo after 26 weeks.
Pharmacokinetics
| Half-life | 8 minutes (Egrifta SV) to 11 minutes (Egrifta WR) in healthy adults |
|---|---|
| Metabolism | No formal metabolism studies in humans (label) |
| Clearance | Not characterized; not studied in kidney or liver impairment (label) |
| Route | Subcutaneous injection; absolute bioavailability under 4%; peak level about 9 minutes after the dose |
Is it FDA-approved?
Yes. The FDA approved tesamorelin as Egrifta on November 10, 2010. The versions sold today are Egrifta SV (named in 2019) and Egrifta WR (approved 2025).
- Brand name: Egrifta (now Egrifta SV and Egrifta WR) (approved 2010)
- FDA prescribing information
- WADA: S2.2.4 Growth hormone releasing factors (named in the 2026 Prohibited List; prohibited at all times)
Sources: [4]
What is Tesamorelin prescribed for?
One use: the label says it "is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." Lipodystrophy here means fat building up around the organs, which can happen in people on long-term HIV treatment.
The label also sets limits: long-term heart safety "has not been established", it "is not indicated for weight loss management as it has a weight neutral effect", and prescribers should weigh stopping it in people whose visceral fat does not go down.
FDA-approved use: Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy
Also studied for
- Fatty liver disease (NAFLD) in people with HIV (12-month randomized trial)
- Cognition in older adults with and without mild cognitive impairment (20-week trial)
- Cognitive impairment in people with HIV (no significant benefit vs standard care)
Sources: [1]
Regulatory timeline
- November 10, 2010FDA approves Egrifta (tesamorelin), 2 mg daily, for excess abdominal fat in HIV-associated lipodystrophy. Source
- July 2019FDA approves the Egrifta SV name for the 2 mg/vial presentation, dosed at 1.4 mg daily. Source
- March 25, 2025FDA approves Egrifta WR, an 11.6 mg vial that provides seven daily 1.28 mg doses. Source
Side effects
In the 26-week placebo-controlled phase of the trials (543 people on tesamorelin, 263 on placebo), the most common side effects were joint pain, injection-site redness and itching, pain in the arms or legs, swelling, and muscle pain. Injection-site reactions overall occurred in 25% of people on tesamorelin versus 14% on placebo.
The more serious risks come from raising growth hormone and IGF-1. HbA1c rose to diabetes range (6.5% or higher) in 5% versus 1% on placebo. By week 26, 47% of people had IGF-1 above 2 standard deviations. The label calls for checking glucose before and during treatment and monitoring IGF-1.
Common
- Injection-site reactions: 17% vs 6% on placebo
- Joint pain (arthralgia): 13% vs 11%
- Pain in arms or legs: 6% vs 5%
- Muscle pain (myalgia): 6% vs 2%
- Swelling of the legs or ankles (peripheral edema): 6% vs 2%
- Tingling or numbness (paresthesia): 5% vs 2%
Serious
- Glucose intolerance or diabetes: HbA1c of 6.5% or higher in 5% vs 1% on placebo
- Elevated IGF-1: the long-term effects of prolonged elevation are unknown
- Fluid retention, including carpal tunnel syndrome
- Hypersensitivity reactions (rash, hives, flushing) in 4% of patients
- Possible reactivation of a past cancer; stop if a malignancy recurs
- Increased mortality reported with growth hormone in acute critical illness
Who should not use it
- Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma
- Active malignancy
- Known hypersensitivity to tesamorelin or the excipients
- Pregnancy
FDA label, Table 1: 26-week placebo-controlled phase of both phase 3 trials (tesamorelin N=543, placebo N=263), and Warnings and Precautions.
Sources: [2]
What does the research show?
Approval rests on two randomized, double-blind phase 3 trials in 816 adults with HIV and excess belly fat. Each had a 26-week main phase and a 26-week extension. In both, tesamorelin reduced visceral fat measured by CT scan, while fat under the skin and body weight barely changed. Triglycerides improved, and people reported less distress about their belly appearance.
The benefit did not last after stopping: people switched to placebo in the extension regained the visceral fat. Published papers report slightly different numbers from the label, because they used different analyses: 15.2% less visceral fat versus 5.0% more on placebo in the first trial, and 10.9% versus 0.6% less in the second.
Outside the approved use, a 12-month trial in people with HIV and fatty liver found a 37% relative drop in liver fat. In cognition, a 20-week trial in older adults found a benefit, but a 2025 trial in people with HIV found no significant difference from standard care.
Visceral fat change in the phase 3 trials (FDA label)
| Phase and study | Tesamorelin | Comparison | Difference (95% CI) |
|---|---|---|---|
| Study 1, weeks 0-26 | -18% | +2% (placebo) | -20% (-24 to -15) |
| Study 2, weeks 0-26 | -14% | -2% (placebo) | -12% (-16 to -7) |
| Study 1, weeks 26-52 | 0% | +22% (switched to placebo) | -17% (-24 to -10) |
| Study 2, weeks 26-52 | -5% | +16% (switched to placebo) | -18% (-24 to -11) |
Mean percent change in visceral adipose tissue on CT at L4-L5, intent-to-treat, last observation carried forward. Weeks 0-26: Study 1, 273 on tesamorelin vs 137 on placebo; Study 2, 270 vs 126. Weeks 26-52 compare people who stayed on tesamorelin with people switched to placebo, measured from week 26: Study 1, 154 vs 50; Study 2, 92 vs 85.
FAQ
Is Tesamorelin FDA-approved?
Yes. It was approved in 2010 as Egrifta, and is sold today as Egrifta SV and Egrifta WR. The approval covers one use: excess abdominal fat in adults with HIV-associated lipodystrophy.
What is Tesamorelin prescribed for?
Reducing visceral belly fat in adults with HIV who have lipodystrophy. Any other use is off-label.
Sources: [1]
Does Tesamorelin cause weight loss?
No. The label says it "has a weight neutral effect" and is not for weight loss. It reduces deep visceral fat while body weight stays about the same; lean mass rose by about 1.2-1.3 kg in the trials.
Is Tesamorelin the same as growth hormone?
No. It is a GHRH analog: it signals the pituitary to release your own growth hormone, rather than replacing it. It is not a steroid.
Sources: [2]
How is Tesamorelin taken?
As a once-daily injection under the skin of the abdomen, rotating sites. Egrifta SV is mixed fresh each day; one Egrifta WR vial gives seven daily doses.
What are the main side effects?
Injection-site reactions, joint and muscle pain, and swelling are the most common. The bigger risks are raised blood sugar and raised IGF-1, which is why the label asks for monitoring.
Sources: [2]
Can people without HIV use Tesamorelin?
It is only approved for adults with HIV-associated lipodystrophy. It has been studied in other groups, such as older adults in a cognition trial, but those uses are not approved.
Is Tesamorelin banned in sport?
Yes. The 2026 WADA Prohibited List names tesamorelin under S2.2.4 (growth hormone releasing factors), prohibited at all times. An athlete with a medical need would have to apply for a therapeutic use exemption.
Sources: [11]
Citations
- EGRIFTA WR (tesamorelin) for injection, prescribing information, 2025 (BLA 022505, supplement 020). accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
- EGRIFTA SV (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- EGRIFTA WR (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
- Drugs@FDA: application 022505 (Egrifta), approval history. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. PMID 18057338
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010. PMID 20101189
- Falutz J, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010. PMID 20554713
- Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019. PMID 31611038
- Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol 2012. PMID 22869065
- Ellis RJ, et al. Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. J Infect Dis 2025. PMID 39813152
- World Anti-Doping Agency: Prohibited List 2026, section S2.2.4 (growth hormone releasing factors). wada-ama.org/en/prohibited-list
Sources
- FDA label (Egrifta WR). EGRIFTA WR (tesamorelin) for injection, prescribing information, 2025 (BLA 022505, supplement 020). accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
- DailyMed (Egrifta SV). EGRIFTA SV (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- DailyMed (Egrifta WR). EGRIFTA WR (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
- Drugs@FDA. Drugs@FDA: application 022505 (Egrifta), approval history. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505
- FDA approval letter, 2019. FDA supplement approval letter, NDA 022505 S-012 and S-013 (Egrifta SV name), July 2019. accessdata.fda.gov/drugsatfda_docs/appletter/2019/022505Orig1s012,%20s013ltr.pdf
- Falutz 2007. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. pubmed.ncbi.nlm.nih.gov/18057338
- Falutz 2010 (JAIDS). Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010. pubmed.ncbi.nlm.nih.gov/20101189
- Falutz 2010 (JCEM). Falutz J, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010. pubmed.ncbi.nlm.nih.gov/20554713
- Stanley 2019. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019. pubmed.ncbi.nlm.nih.gov/31611038
- Baker 2012. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol 2012. pubmed.ncbi.nlm.nih.gov/22869065
- Ellis 2025. Ellis RJ, et al. Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. J Infect Dis 2025. pubmed.ncbi.nlm.nih.gov/39813152
- WADA. World Anti-Doping Agency: Prohibited List 2026, section S2.2.4 (growth hormone releasing factors). wada-ama.org/en/prohibited-list
Administration & storage
- Administration
- Subcutaneous injection (PMID: 31611038250383573890548839813152215160302535845025895899)
- Storage
- Storage conditions for tesamorelin are not stated in the reviewed abstracts.
- Cautions
- Injection-site reactions (erythema, localised complaints) have been reported in clinical trials of tesamorelin; these were more frequent than placebo but none judged serious in the NAFLD trial.,Growth hormone-related adverse effects including arthralgia, myalgia, paresthesia, headache, and peripheral oedema have been reported in clinical trials.,A transient early increase in fasting glucose was observed at 2 weeks in one trial (mean change +9 mg/dL vs +2 mg/dL placebo; P=0.03), though changes at 6 months were not significant. Clinicians should monitor glucose, particularly in patients with diabetes or pre-diabetes.,Discontinuation of tesamorelin results in prompt reaccumulation of visceral adipose tissue.,Long-term safety data are limited; abstracts consistently call for further research on extended treatment duration and durability of effects. Use outside approved indications (e.g., for orthopaedic or sports performance purposes) lacks safety and efficacy evidence.,Tesamorelin is prohibited by WADA; athletes should be aware of antidoping implications.,Sterile injection technique is essential when administering any subcutaneous peptide.
Legal & regulatory status
Approved by the US Food and Drug Administration in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Described as the only FDA-approved therapy to treat abdominal fat…
GHRH and its synthetic analogues, including tesamorelin, are prohibited by the World Anti-Doping Agency (WADA).
Not stated in reviewed literature — requires manual verification
What it's studied for
- HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV Human RCT
- Tesamorelin 2 mg SC daily for 6 months significantly reduced visceral adipose tissue (mean change -34 cm² vs +8 cm² placebo; treatment effect -42 cm²; P=0.005) and liver fat (net treatment effect -2.9% lipid-to-water percentage; P=0.003) in 50 HIV-infected patients with abdominal fat accumulation. PMID 25038357 Stanley TL et al. JAMA 2014
- Systematic review of two 26-week Phase 3 RCTs: tesamorelin SC significantly reduced VAT and waist circumference in HIV-associated lipodystrophy; VAT reduction maintained at 52 weeks with continued therapy; discontinuation led to VAT reaccumulation. Serious adverse events occurred in <4% of patients. PMID 21668043 Dhillon S. Drugs 2011
- Systematic review and meta-analysis of 4 RCTs (909 patients): tesamorelin 2 mg significantly reduced VAT (MD -21.47 cm²; P=0.002), waist circumference (MD -1.61 cm; P<0.00001), trunk fat (MD -1.20 kg; P<0.00001), and increased lean body mass (MD 1.42 kg; P<0.00001). Growth hormone-related adverse effects observed. PMID 42538058 Mohammed Ditta A et al. J Int Assoc Provid AIDS Care 2026
- Meta-analysis of 5 RCTs: tesamorelin significantly reduced VAT (MD -27.71 cm²), trunk fat, limb fat, hepatic fat percentage (MD -4.28%), and waist circumference; increased lean body mass (MD 1.42 kg). No significant change in subcutaneous fat, BMI, or CD4+ T-cell counts. Adverse events included arthralgia, myalgia, par PMID 41545261 Badran AS et al. Obes Res Clin Pract 2026
- In 38 PWH on integrase inhibitor (INSTI)-based regimens, tesamorelin 2 mg once daily vs placebo for 12 months led to significant reductions in visceral fat (median -25 vs +14 cm²; P=0.001), hepatic fat (-4.2% vs -0.5%; P=0.01), and trunk-to-appendicular fat ratio (P=0.03), with no exacerbation of glycemic control. PMID 38905488 Russo SC et al. AIDS 2024
- Randomized double-blind multicentre trial of 61 HIV-infected patients with NAFLD: tesamorelin 2 mg daily vs placebo for 12 months reduced hepatic fat fraction (absolute effect -4.1%, 95% CI -7.6 to -0.7; P=0.018); 35% of tesamorelin vs 4% of placebo group achieved HFF <5% (P=0.0069). Fasting glucose and HbA1c not signi PMID 31611038 Stanley TL et al. Lancet HIV 2019
- Post-hoc analysis of two Phase 3 trials (tesamorelin 2 mg n=543, placebo n=263): metabolic syndrome (NCEP criteria), triglycerides >1.7 mmol/L, and white race predicted greater VAT reduction at 6 months. Odds of VAT reduction to <140 cm² were 3.9× greater for tesamorelin vs placebo. PMID 26457580 Mangili A et al. PLoS One 2015
- HIV-associated non-alcoholic fatty liver disease (NAFLD) / metabolic dysfunction-associated steatotic liver disease (MASLD) Human RCT
- Tesamorelin 2 mg daily for 12 months significantly reduced hepatic fat fraction and prevented fibrosis progression in HIV-associated NAFLD compared to placebo. PMID 31611038 Stanley TL et al. Lancet HIV 2019
- Hepatic transcriptomic analysis from paired biopsies in a RCT: tesamorelin increased oxidative phosphorylation gene sets and decreased inflammation/tissue repair/cell division gene sets; correlated with improved fibrosis-related gene score. PMID 32701508 Fourman LT et al. JCI Insight 2020
- Tesamorelin led to significant reductions in plasma VEGFA, TGFB1, and CSF1 vs placebo; reductions in VEGFA and CSF1 correlated with decline in NAFLD activity score; decreases in TGFB1 and CSF1 associated with reduced fibrosis gene score. PMID 34006921 Fourman LT et al. Sci Rep 2021
- In HIV-associated NAFLD, visceral fat was positively associated with ALT (P=0.01); tesamorelin VAT responders experienced greater reductions in ALT (-8.9 vs +1.4 U/L; P=0.004) and AST (-3.8 vs +0.4 U/L; P=0.04) vs non-responders over 26 weeks. PMID 28832410 Fourman LT et al., AIDS (2017)
- Body composition improvement (visceral fat, lean mass, muscle quality) in people with HIV Human RCT
- Secondary analysis of two RCTs: tesamorelin responders (VAT decrease ≥8%) showed significantly greater increases in trunk muscle density (coefficient 1.56–4.86 HU; all P<0.005) and lean muscle area of all four truncal groups compared to placebo over 26 weeks. PMID 31237318 Adrian S et al. J Frailty Aging 2019
- Tesamorelin increased VAT and SAT density (fat quality) independent of fat quantity changes over 26 weeks in PWH (VAT +6.2 vs +0.3 HU placebo; P<0.0001; SAT +4.0 vs +0.3 HU; P<0.0001). PMID 33756511 Lake JE et al. AIDS 2021
- Metabolic effects: triglycerides, inflammatory markers, cardiovascular risk markers Human RCT
- Phase 3 RCT of 410 HIV-infected patients: tesamorelin significantly decreased tPA antigen (P<0.05) and changes in inflammatory markers were associated with VAT change; modest beneficial effects on adiponectin and fibrinolytic markers observed. PMID 21516030 Stanley TL et al. AIDS 2011
- In 60 obese subjects with reduced GH, tesamorelin 2 mg daily for 12 months significantly reduced VAT (-35 cm² treatment effect; P=0.003), carotid IMT (-0.04 mm; P=0.02), log CRP (-0.15 mg/L; P=0.04), and triglycerides (-37 mg/dL; P=0.02) vs placebo. No significant effects on fasting or 2-hr glucose or HbA1c. PMID 23015655 Makimura H et al. J Clin Endocrinol Metab 2012
- Phase 3 RCT: tesamorelin responders (≥8% VAT reduction) had greater triglyceride reductions at 26 and 52 weeks and attenuated changes in fasting glucose and HbA1c vs non-responders. PMID 22495074 Stanley TL et al. Clin Infect Dis 2012
- Glycemic safety in type 2 diabetes Human RCT
- 12-week RCT of 53 patients with type 2 diabetes: no significant differences between placebo, 1 mg, and 2 mg tesamorelin groups in relative insulin response, fasting glucose, HbA1c, or diabetes control. Total cholesterol and non-HDL cholesterol significantly decreased from baseline in the 2 mg group (P<0.05 vs placebo). PMID 28617838 Clemmons DR et al. PLoS One 2017
- Neurocognitive function in HIV with abdominal obesity Human RCT
- Phase 2 RCT (n=73): tesamorelin 2 mg SC daily vs standard of care for 6 months showed trend toward improved neurocognitive performance (P=0.060) but between-group difference was not significant (P=0.673). Tesamorelin group had greater reduction in waist circumference (median difference -2.7 cm; P=0.015). Study was unde PMID 39813152 Ellis RJ et al. J Infect Dis 2025
- Mitochondrial function (phosphocreatine recovery) in obese adults with reduced GH Human RCT
- 12-month RCT of 39 obese adults with reduced GH: significant positive relationship between increases in IGF-1 and improvements in PCr recovery (R=0.56; P=0.01), with stronger association among tesamorelin-treated subjects only (R=0.71; P=0.03), suggestive of improvements in mitochondrial function. PMID 24178787 Makimura H et al. J Clin Endocrinol Metab 2014
- Physical function in older adults with HIV (ongoing trial) Human RCT
- TRIUMPH trial protocol: two-site, double-blind RCT of 100 sedentary older adults (aged 50-80) with HIV who are frail or at risk for frailty and have excess abdominal adiposity. Participants randomized to tesamorelin or placebo as adjunct to home-based exercise for 24 weeks. Endpoints include physical function, muscle c PMID 42419889 Erlandson KM et al. BMJ Open 2026 (TRIUMPH protocol)
- Orthopaedic / sports medicine / musculoskeletal injury Animal studies only
- Narrative review: tesamorelin, approved for HIV-associated lipodystrophy, has no supporting orthopaedic evidence. Remains investigational for musculoskeletal indications. PMID 41476424 Mayfield CK et al. Am J Sports Med 2026
- Structured narrative review: growth hormone axis secretagogues including tesamorelin remain investigational for sports medicine, with uncertain safety profiles and product quality concerns. PMID 42160466 Villegas Meza AD et al. JBJS Rev 2026
Safety signals
- Injection-site reactions (erythema, localised complaints): more frequent in tesamorelin than placebo groups in clinical trials, though none judged serious in the NAFLD RCT. PMID 31611038
- Injection-site reactions including erythema reported in meta-analysis of RCTs. PMID 41545261
- Arthralgia reported as an adverse event in RCTs (a known GH-related effect). PMID 41545261
- Myalgia reported as an adverse event in RCTs. PMID 41545261
- Paresthesia reported as an adverse event in RCTs. PMID 41545261
- Headache reported as a treatment-emergent adverse event associated with GH therapy. PMID 21668043
- Peripheral oedema reported as a treatment-emergent adverse event associated with GH therapy. PMID 21668043
- Transient early increase in fasting glucose at 2 weeks (mean +9 mg/dL vs +2 mg/dL placebo; P=0.03), not sustained at 6 months. PMID 25038357
- Higher discontinuation rates with tesamorelin vs placebo in meta-analysis (RR 2.25; 95% CI 0.98–5.17; P=0.06), though not statistically significant. PMID 42538058
- Treatment-emergent serious adverse events in <4% of patients during 26 weeks of therapy in Phase 3 trials, most being injection-site reactions or GH-related effects. PMID 21668043
- Visceral adipose tissue reaccumulates promptly upon discontinuation of tesamorelin. PMID 21668043
- Reported adverse effects across GHRH analogue class in self-administration context include endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, musculoskeletal symptoms, and injection-site reactions. PMID 42395176
Contraindications
- Active malignancy: participants with malignancy were excluded from the neurocognitive Phase 2 RCT of tesamorelin, reflecting standard GH-axis safety concerns. PMID 39813152
- Conditions other than HIV causing neurocognitive impairment were an exclusion criterion, indicating that tesamorelin has not been studied in this context. PMID 39813152
- Active substance use disorder was an exclusion criterion in the neurocognitive RCT. PMID 39813152
Protocol
2000 mcg subcutaneous injection, once daily. Cycle: 3-6 months.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| subcutaneous injection | 2 mg once daily | 12 months (followed by 6-month open-label phase) | human | Research PMID 31611038 |
| subcutaneous injection | 2 mg once daily | 6 months | human | Research PMID 25038357 |
| subcutaneous injection | 2 mg once daily | 12 months | human | Research PMID 38905488 |
| subcutaneous injection | 2 mg subcutaneously daily | 6 months | human | Research PMID 39813152 |
| not specified in abstract (study of type 2 diabetes patients) | 1 mg or 2 mg once daily (3 groups: placebo, 1 mg, 2 mg) | 12 weeks | human | Research PMID 28617838 |
| not specified in abstract (obese subjects with reduced GH) | 2 mg once daily | 12 months | human | Research PMID 23015655 |
| not specified in abstract | 2 mg (implied, from same trial as PMID 23015655) | 12 months | human | Research PMID 24178787 |
| not specified in abstract | 2 mg vs. identical placebo daily | 6 months | human | Research PMID 37029031 |
| subcutaneous injection | 1 mg or 2 mg subcutaneously daily for 14 consecutive days | 14 days | human | Research PMID 25358450 |
| subcutaneous injection | 1 mg or 2 mg subcutaneously daily for 14 consecutive days | 14 days | human | Research PMID 25895899 |
| subcutaneous injection | 2 mg subcutaneously once daily for 2 weeks | 2 weeks | human | Research PMID 20943777 |
| subcutaneous injection | 2 mg subcutaneously daily | 26 weeks | human | Research PMID 21516030 |
| subcutaneous injection | tesamorelin (dose not explicitly stated in abstract; 2 mg inferred from study design) | 26 weeks, with 26-week extension | human | Research PMID 22495074 |
| subcutaneous injection | 2000 mcg | once daily · 3-6 months | HIV-positive adults with lipodystrophy (visceral adiposity); also adopted by biohackers for body composition | [Community] |
| subcutaneous injection | 1000 mcg | once daily · 3-6 months | healthy adult biohackers seeking body composition improvement or IGF-1 elevation without full clinical dose | [Community] |
| subcutaneous injection | 2000 mcg | once daily, administered pre-sleep · 12-26 weeks | biohackers and longevity-focused adults seeking GH pulse optimization and anti-aging effects | [Community] |
| subcutaneous injection | 2000 mcg | once daily (morning, fasted) · 12 weeks | body composition-focused biohackers prioritizing visceral fat loss | [Community] |
| subcutaneous injection | 2000 mcg | once daily · 16-26 weeks | older adults (40+) or those with clinically elevated visceral fat, often under TRT or HRT | [Community] |
| subcutaneous injection | 500 mcg | once daily · 4-8 weeks | cautious first-time users or those combining tesamorelin with other GH-axis peptides | [Community] |
| subcutaneous injection | 2000 mcg | 5 days on / 2 days off · 12-24 weeks | biohackers managing cost and attempting to reduce receptor desensitization concerns | [Community] |
| subcutaneous injection | 1000 mcg | once daily · 8-12 weeks | women biohackers or those with lower body weight seeking body composition benefits with reduced side-effect risk | [Community] |
| subcutaneous injection | 2000 mcg | once daily · 12 weeks on, 4 weeks off (cyclical) | long-term biohackers using tesamorelin as part of an ongoing anti-aging or body composition stack | [Community] |
Blends containing this peptide
All studies (27)
- PMID 21516030 Human RCT
Metabolic effects: triglycerides, inflammatory markers, cardiovascular risk markers - PMID 21668043 Human RCT
HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV - PMID 22495074 Human RCT
Metabolic effects: triglycerides, inflammatory markers, cardiovascular risk markers - PMID 23015655 Human RCT
Metabolic effects: triglycerides, inflammatory markers, cardiovascular risk markers - PMID 24178787 Human RCT
Mitochondrial function (phosphocreatine recovery) in obese adults with reduced GH - PMID 25038357 Human RCT
HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV - PMID 26457580 Human RCT
HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV - PMID 28617838 Human RCT
Glycemic safety in type 2 diabetes - PMID 28832410 Human RCT
HIV-associated non-alcoholic fatty liver disease (NAFLD) / metabolic dysfunction-associated steatoti - PMID 31237318 Human RCT
Body composition improvement (visceral fat, lean mass, muscle quality) in people with HIV - PMID 31611038 Human RCT
HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV - PMID 32701508 Human RCT
HIV-associated non-alcoholic fatty liver disease (NAFLD) / metabolic dysfunction-associated steatoti - PMID 33756511 Human RCT
Body composition improvement (visceral fat, lean mass, muscle quality) in people with HIV - PMID 34006921 Human RCT
HIV-associated non-alcoholic fatty liver disease (NAFLD) / metabolic dysfunction-associated steatoti - PMID 38905488 Human RCT
HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV - PMID 39813152 Human RCT
Neurocognitive function in HIV with abdominal obesity - PMID 41545261 Human RCT
HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV - PMID 42419889 Human RCT
Physical function in older adults with HIV (ongoing trial) - PMID 42538058 Human RCT
HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV - PMID 20943777
2 mg subcutaneously once daily for 2 weeks subcutaneous injection (human) - PMID 25358450
1 mg or 2 mg subcutaneously daily for 14 consecutive days subcutaneous injection (human) - PMID 25895899
1 mg or 2 mg subcutaneously daily for 14 consecutive days subcutaneous injection (human) - PMID 37029031
2 mg vs. identical placebo daily not specified in abstract (human) - PMID 41138283
- PMID 41476424 Animal studies only
Orthopaedic / sports medicine / musculoskeletal injury - PMID 42160466 Animal studies only
Orthopaedic / sports medicine / musculoskeletal injury - PMID 42395176
Reported adverse effects across GHRH analogue class in self-administration context include endocrine/metabolic disturbances (prolactin and cortisol elevations,